comparemela.com
Home
Live Updates
Phase 2 Trial Data Show That Novel Antibiotic Led to 96% Cur
Phase 2 Trial Data Show That Novel Antibiotic Led to 96% Cur
Phase 2 Trial Data Show That Novel Antibiotic Led to 96% Cure Rate for C diff Infection
Iberzaplstat was non-inferior to standard of care vancomycin, was safe and tolerable, and will advance into a phase 3 trial.
Related Keywords
United States ,
Jo Panuwat ,
Stuart Johnson ,
Robertj Deluccia ,
Kevin Garey ,
Acrux Pharmaceuticals ,
University Of Houston College Pharmacy ,
Us Centers For Disease ,
Loyola University ,
Pfizer ,
Acurx Scientific Advisory Board ,
Houston College ,
Disease Control ,
Awareness Month ,